PlainRecalls
FDA Drug Moderate Class II Terminated

Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use. Single-Dose Prefilled Syringe. Product of France, Manufactured by: Genentech, Inc. A Member of the Roche Group, South San Francisco, CA 9480-4990. NDC: 50242-215-01

Reported: July 14, 2021 Initiated: June 9, 2021 #D-0650-2021

Product Description

Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use. Single-Dose Prefilled Syringe. Product of France, Manufactured by: Genentech, Inc. A Member of the Roche Group, South San Francisco, CA 9480-4990. NDC: 50242-215-01

Reason for Recall

Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.

Details

Recalling Firm
Genentech Inc
Units Affected
88,620 prefilled syringes
Distribution
Product was distributed nationwide
Location
South San Francisco, CA

Frequently Asked Questions

What product was recalled?
Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use. Single-Dose Prefilled Syringe. Product of France, Manufactured by: Genentech, Inc. A Member of the Roche Group, South San Francisco, CA 9480-4990. NDC: 50242-215-01. Recalled by Genentech Inc. Units affected: 88,620 prefilled syringes.
Why was this product recalled?
Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 14, 2021. Severity: Moderate. Recall number: D-0650-2021.